ReviewAntibiotics (Basel, Switzerland)2019
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Review in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 330 citations in OpenAlex.
- Antimicrobial Activity of a Polymyxin A-like Compound and Characterisation of the Cognate Biosynthetic Gene Cluster Within the Genome of the ProducingAntibiotics (Basel, Switzerland) · 2026Article
- A double-layer plate method for rapid screening of cell wall-targeting antibiotic producers using a microbial whole-cell biosensor.Applied and environmental microbiology · 2026Article
- What's in a Name? Etymology and History of Antibacterials and Antifungals.Open forum infectious diseases · 2026Review
- Euglena gracilis as a high-throughput screening platform for antibacterial activity, cytotoxicity and membrane permeability in a one-step and cost-effective assay.The Journal of antibiotics · 2026Article
- Structure-Based Strategy Reveals a Novel Ligand Binding Site inACS omega · 2026Article
- Rapid Adaptive Evolution under Combination Therapy inACS infectious diseases · 2026Article
- Isolation and characterization of broad-rangeMicrobiology (Reading, England) · 2026Article
- Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections.Microbiology spectrum · 2026Article
- Inactivation of the sco2730/2731 copper chaperone-transporter system in Streptomyces coelicolor and its orthologs in Streptomyces venezuelae, together with chromosomal end deletion, greatly enhances secondary metabolism.Microbial cell factories · 2026Article
- Article
- Artificial intelligence drives the identification and screening of novel antibiotics and antimicrobial peptides.Briefings in bioinformatics · 2026Review
- A two-step screen identifies a small molecule that disrupts membrane voltage and is effective against growing and persister gram-negative bacteria.Microbiology spectrum · 2026Article
- Advances in deep learning for antimicrobial research.Frontiers in microbiology · 2026Review
- Antibacterial Drug Discovery: Deep Learning Successes and Challenges through the Structural Biology Lens.Computational and structural biotechnology journal · 2026Review
- Antibiotic Resistance Crisis: From Bacterial Bioprospecting to Artificial Intelligence.Environmental microbiology reports · 2025Review
- Enhancing the Solubility and Antibacterial Efficacy of Sulfamethoxazole by Incorporating Functionalized PLGA and Graphene Oxide Nanoparticles into the Crystal Structure.Pharmaceutics · 2025Article
- Rational antibiotic prescribing practices among dentists in Turkey: a cross-sectional study.BMC oral health · 2025Article
- Synthesis and antimicrobial activity of thiophene-functionalized Ag(I) and Au(I) N-heterocyclic carbene complexes against ampicillin-resistant Staphylococcus aureus.Scientific reports · 2025Article
- Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections.Scientific reports · 2025Article
- Assessing the Antibiotic Resistance in Food Lactic Acid Bacteria: Risks in the Era of Widespread Probiotic Use.Food science & nutrition · 2025Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Given the increase in antibiotic-resistant bacteria, alongside the alarmingly low rate of newly approved antibiotics for clinical usage, we are on the verge of not having effective treatments for many common infectious diseases. Historically, antibiotic discovery has been crucial in outpacing resistance and success is closely related to systematic procedures-platforms-that have catalyzed the antibiotic golden age, namely the Waksman platform, followed by the platforms of semi-synthesis and fully synthetic antibiotics. Said platforms resulted in the major antibiotic classes: aminoglycosides, amphenicols, ansamycins, beta-lactams, lipopeptides, diaminopyrimidines, fosfomycins, imidazoles, macrolides, oxazolidinones, streptogramins, polymyxins, sulphonamides, glycopeptides, quinolones and tetracyclines. During the genomics era came the target-based platform, mostly considered a failure due to limitations in translating drugs to the clinic. Therefore, cell-based platforms were re-instituted, and are still of the utmost importance in the fight against infectious diseases. Although the antibiotic pipeline is still lackluster, especially of new classes and novel mechanisms of action, in the post-genomic era, there is an increasingly large set of information available on microbial metabolism. The translation of such knowledge into novel platforms will hopefully result in the discovery of new and better therapeutics, which can sway the war on infectious diseases back in our favor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.